Search Results - "FAROUX, Roger"

Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study by Edeline, Julien, Benabdelghani, Meher, Bertaut, Aurélie, Watelet, Jérôme, Hammel, Pascal, Joly, Jean-Paul, Boudjema, Karim, Fartoux, Laetitia, Bouhier-Leporrier, Karine, Jouve, Jean-Louis, Faroux, Roger, Guerin-Meyer, Véronique, Kurtz, Jean-Emmanuel, Assénat, Eric, Seitz, Jean-François, Baumgaertner, Isabelle, Tougeron, David, de la Fouchardière, Christelle, Lombard-Bohas, Catherine, Boucher, Eveline, Stanbury, Trevor, Louvet, Christophe, Malka, David, Phelip, Jean-Marc

“…No standard adjuvant treatment currently is recommended in localized biliary tract cancer (BTC) after surgical resection. We aimed to assess whether…”
Get full text

Capecitabine plus oxaliplatin (XELOX) versus 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) as first‐line treatment for metastatic colorectal cancer by Ducreux, Michel, Bennouna, Jaafar, Hebbar, Mohamed, Ychou, Marc, Lledo, Gérard, Conroy, Thierry, Adenis, Antoine, Faroux, Roger, Rebischung, Christine, Bergougnoux, Loic, Kockler, Leila, Douillard, Jean‐Yves

“…A regimen consisting of 5‐fluorouracil/leucovorin plus oxaliplatin (FOLFOX‐6) is widely used in France in the first‐line treatment of metastatic colorectal…”
Get full text

Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial by Aparicio, Thomas, Bennouna, Jaafar, Le Malicot, Karine, Boige, Valérie, Taieb, Julien, Bouché, Olivier, Phelip, Jean-Marc, François, Eric, Borel, Christian, Faroux, Roger, Dahan, Laetitia, Bachet, Jean-Baptiste, Egreteau, Joelle, Kaminsky, Marie-Christine, Gornet, Jean-Marc, Cojocarasu, Oana, Gasmi, Mohamed, Guerin-Meyer, Véronique, Lepage, Côme, Ghiringhelli, François

“…Background Identifying patients with metastatic colorectal cancer who will have an early disease progression during induction chemotherapy (IC) and identifying…”
Get full text

Predictive value of vascular endothelial growth factor polymorphisms for maintenance bevacizumab efficacy in metastatic colorectal cancer: an ancillary study of the PRODIGE 9 phase III trial by de Rauglaudre, Bernadette, Sibertin-Blanc, Camille, Fabre, Aurélie, Le Malicot, Karine, Bennouna, Jaafar, Ghiringhelli, François, Taïeb, Julien, Boige, Valérie, Bouché, Olivier, Chatellier, Thierry, Faroux, Roger, François, Eric, Jacquot, Stéphane, Genet, Dominique, Mulot, Claire, Olschwang, Sylviane, Seitz, Jean-François, Aparicio, Thomas, Dahan, Laetitia

“…Background: Several studies have reported the impact of single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (VEGF) pathway genes on…”
Get full text

The Characteristics of Diverticular Disease in Caribbean Population: A Control Group Study by Gelu-Simeon, Moana, Schnee, Matthieu, Lafrance, Marie-Josée, Plazy-Chabrand, Pauline, Schneck, Anne-Sophie, Saint-Georges, Georgette, Alexis, Marceline, Delumeau, Stéphanie, Montigny, Philippe, Faroux, Roger, Dimet, Jérome, Saillard, Eric

“…Background. Diverticulosis is not well characterized in the Caribbeans. Our aim was to compare the anatomical presentation of colonic diverticulosis in African…”
Get full text

Comparison of 4 Screening Methods for Detecting Fluoropyrimidine Toxicity Risk: Identification of the Most Effective, Cost-Efficient Method to Save Lives by Capitain, Olivier, Seegers, Valérie, Metges, Jean-Philippe, Faroux, Roger, Stampfli, Claire, Ferec, Marc, Budnik, Tamara Matysiak, Senellart, Hélène, Rossi, Valérie, Blouin, Nadège, Dauvé, Jonathan, Campone, Mario

“…Background: Fluoropyrimidines (FPs) carry around 20% risk of G3-5 toxicity and 0.2-1% risk of death, due to dihydropyrimidine dehydrogenase (DPD) deficiency…”
Get full text

High-Density of FcγRIIIA+ (CD16+) Tumor-Associated Neutrophils in Metastases Improves the Therapeutic Response of Cetuximab in Metastatic Colorectal Cancer Patients, Independently of the HLA-E/CD94-NKG2A Axis by Denis Musquer, Marie, Jouand, Nicolas, Pere, Morgane, Lamer, Juliette Eugène, Bézieau, Stéphane, Matysiak, Tamara, Faroux, Roger, Caroli Bosc, François-Xavier, Rousselet, Marie-Christine, Leclair, François, Mosnier, Jean-François, Toquet, Claire, Gervois, Nadine, Bossard, Céline

“…Antibody-dependent cellular cytotoxicity (ADCC) in the anti-tumor effect of cetuximab in metastatic colorectal cancer (mCRC) is only based on the impact of…”
Get full text

Low-penetrance alleles predisposing to sporadic colorectal cancers: a French case-controlled genetic association study by Küry, Sébastien, Buecher, Bruno, Robiou-du-Pont, Sébastien, Scoul, Catherine, Colman, Hélène, Le Neel, Tanguy, Le Houérou, Claire, Faroux, Roger, Ollivry, Jean, Lafraise, Bernard, Chupin, Louis-Dominique, Sébille, Véronique, Bézieau, Stéphane

“…Sporadic colorectal cancers (CRC) are multifactorial diseases resulting from the combined effects of numerous genetic, environmental and behavioral risk…”
Get full text

Gemox versus surveillance following surgery of localized biliary tract cancer: Results of the PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial by Edeline, Julien, Bonnetain, Franck, Phelip, Jean Marc, Watelet, Jérôme, Hammel, Pascal, Joly, Jean-Paul, Ben Abdelghani, Meher, Rosmorduc, Olivier, Bouhier-Leporrier, Karine, Jouve, Jean-Louis, Faroux, Roger, Guerin Meyer, Véronique, Assenat, Eric, Seitz, Jean Francois, Malka, David, Louvet, Christophe, Bertaut, Aurelie, Juzyna, Beata, Stanbury, Trevor, Boucher, Eveline

“…Abstract only 225 Background: No standard post-surgery adjuvant treatment is currently recommended in localized biliary tract cancer (BTC). Gemcitabine…”
Get full text

Ultraflex precision colonic stent placement for palliation of malignant colonic obstruction: a prospective multicenter study by Repici, Alessandro, MD, Fregonese, Diego, MD, Costamagna, Guido, MD, Dumas, Remi, MD, Kähler, Georg, MD, Meisner, Søren, MD, Giovannini, Marc, MD, Freeman, Jan, MD, Petruziello, Lucio, MD, Hervoso, Cristina, MD, Comunale, Salvatore, MD, Faroux, Roger, MD

“…Background Many patients who develop obstructive colonic symptoms secondary to inoperable colorectal cancer will require palliative treatment. A minimally…”
Get full text

Combinations of Cytochrome P450 Gene Polymorphisms Enhancing the Risk for Sporadic Colorectal Cancer Related to Red Meat Consumption by KÜRY, Sébastien, BUECHER, Bruno, OLLIVRY, Jean, LAFRAISE, Bernard, CHUPIN, Louis-Dominique, BEZIEAU, Stéphane, ROBIOU-DU-PONT, Sébastien, SCOUL, Catherine, SEBILLE, Véronique, COLMAN, Hélène, LE HOUEROU, Claire, LE NEEL, Tanguy, BOURDON, Jérémie, FAROUX, Roger

“…Susceptibility to sporadic colorectal cancers (CRC) is generally thought to be the sum of complex interactions between environmental and genetic factors, all…”
Get full text

Middle-term mortality and re-bleeding after initial diverticular bleeding: A nationwide study of 365 mostly elderly French patients by Lorenzo, Diane, Gallois, Claire, Lahmek, Pierre, Lesgourgues, Bruno, Champion, Christine, Charpignon, Claire, Faroux, Roger, Bour, Bruno, Remy, André-Jean, Naouri, Chantal, Picon, Magali, Poncin, Eric, Macaigne, Gilles, Seyrig, Jacques-Arnaud, Bernardini, David, Bellaïche, Guy, Grasset, Denis, Henrion, Jean, Heluwaert, Frédéric, Piperaud, René, Bordes, Gilbert, Bourhis, Francois, Arpurt, Jean-Pierre, Pariente, Alexandre, Nahon, Stéphane

“…Background and aims The aim of this study was to determine the mortality and re-bleeding rates, and the risk factors involved, in a cohort of patients with…”
Get full text

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer by Conroy, Thierry, Hammel, Pascal, Hebbar, Mohamed, Ben Abdelghani, Meher, Wei, Alice C, Raoul, Jean-Luc, Choné, Laurence, Francois, Eric, Artru, Pascal, Biagi, James J, Lecomte, Thierry, Assenat, Eric, Faroux, Roger, Ychou, Marc, Volet, Julien, Sauvanet, Alain, Breysacher, Gilles, Di Fiore, Frédéric, Cripps, Christine, Kavan, Petr, Texereau, Patrick, Bouhier-Leporrier, Karine, Khemissa-Akouz, Faiza, Legoux, Jean-Louis, Juzyna, Béata, Gourgou, Sophie, O’Callaghan, Christopher J, Jouffroy-Zeller, Claire, Rat, Patrick, Malka, David, Castan, Florence, Bachet, Jean-Baptiste

“…In a prospective, randomized trial involving patients with resected pancreatic cancer, adjuvant combination chemotherapy with FOLFIRINOX resulted in a median…”
Get full text

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial by Hammel, Pascal, Fabienne, Portales, Mineur, Laurent, Metges, Jean-Philippe, Andre, Thierry, De La Fouchardiere, Christelle, Louvet, Christophe, El Hajbi, Farid, Faroux, Roger, Guimbaud, Rosine, Tougeron, David, Bouche, Olivier, Lecomte, Thierry, Rebischung, Christine, Tournigand, Christophe, Cros, Jerome, Kay, Richard, Hamm, Adam, Gupta, Anu, Bachet, Jean-Baptiste, El Hariry, Iman

“…This Phase IIb (NCT02195180) open-label study evaluated erythrocyte-encapsulated asparaginase (eryaspase) in combination with chemotherapy in second-line…”
Get full text

Early evaluation using a radiomic signature of unresectable hepatic metastases to predict outcome in patients with colorectal cancer treated with FOLFIRI and bevacizumab by Dohan, Anthony, Gallix, Benoit, Guiu, Boris, Le Malicot, Karine, Reinhold, Caroline, Soyer, Philippe, Bennouna, Jaafar, Ghiringhelli, Francois, Barbier, Emilie, Boige, Valérie, Taieb, Julien, Bouché, Olivier, François, Eric, Phelip, Jean-Marc, Borel, Christian, Faroux, Roger, Seitz, Jean-Francois, Jacquot, Stéphane, Ben Abdelghani, Meher, Khemissa-Akouz, Faiza, Genet, Dominique, Jouve, Jean Louis, Rinaldi, Yves, Desseigne, Françoise, Texereau, Patrick, Suc, Etienne, Lepage, Come, Aparicio, Thomas, Hoeffel, Christine

“…The objective of this study was to build and validate a radiomic signature to predict early a poor outcome using baseline and 2-month evaluation CT and to…”
Get more information

Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France PRODIGE-GERCOR cohort study by Pagès, F, André, T, Taieb, J, Vernerey, D, Henriques, J, Borg, C, Marliot, F, Ben Jannet, R, Louvet, C, Mineur, L, Bennouna, J, Desrame, J, Faroux, R, Kirilovsky, A, Duval, A, Laurent-Puig, P, Svrcek, M, Hermitte, F, Catteau, A, Galon, J, Emile, J-F

“…The Immunoscore (IS), which prognostically classifies stage I-III colon cancer (CC) patients, was evaluated in the International Duration Evaluation of…”
Get full text

Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial by André, Thierry, Vernerey, Dewi, Mineur, Laurent, Bennouna, Jaafar, Desrame, Jérôme, Faroux, Roger, Fratte, Serge, Hug de Larauze, Marine, Paget-Bailly, Sophie, Chibaudel, Benoist, Bez, Jeremie, Dauba, Jérôme, Louvet, Christophe, Lepere, Céline, Dupuis, Olivier, Becouarn, Yves, Mabro, May, Egreteau, Joëlle, Bouche, Olivier, Deplanque, Gaël, Ychou, Marc, Galais, Marie Pierre, Ghiringhelli, François, Dourthe, Louis Marie, Bachet, Jean-Baptiste, Khalil, Ahmed, Bonnetain, Franck, de Gramont, Aimery, Taieb, Julien

“…Purpose Reduction of adjuvant treatment duration may decrease toxicities without loss of efficacy in stage III colon cancer. This could offer clear advantages…”
Get full text

Evaluation of two nutritional scores' association with systemic treatment toxicity and survival in metastatic colorectal cancer: an AGEO prospective multicentre study by Gallois, Claire, Artru, Pascal, Lièvre, Astrid, Auclin, Edouard, Lecomte, Thierry, Locher, Christophe, Marthey, Lysiane, Zaimi, Yosra, Faroux, Roger, Pernot, Simon, Barret, Maximilien, Taieb, Julien

“…The Patient-Generated Subjective Global Assessment (PG-SGA) is currently the standard nutritional assessment tool for patients with cancer. In a retrospective…”
Get full text

Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9) by Aparicio, Thomas, Ghiringhelli, Francois, Boige, Valérie, Le Malicot, Karine, Taieb, Julien, Bouché, Olivier, Phelip, Jean-Marc, François, Eric, Borel, Christian, Faroux, Roger, Dahan, Laetitia, Jacquot, Stéphane, Genet, Dominique, Khemissa, Faiza, Suc, Etienne, Desseigne, Françoise, Texereau, Patrick, Lepage, Come, Bennouna, Jaafar

“…Purpose Conflicting results are reported for maintenance treatment with bevacizumab during chemotherapy-free intervals (CFI) in metastatic colorectal cancer…”
Get full text

Pravastatin combination with sorafenib does not improve survival in advanced hepatocellular carcinoma by Jouve, Jean-Louis, Lecomte, Thierry, Bouché, Olivier, Barbier, Emilie, Khemissa Akouz, Faiza, Riachi, Ghassan, Nguyen Khac, Eric, Ollivier-Hourmand, Isabelle, Debette-Gratien, Maryline, Faroux, Roger, Villing, Anne-Laure, Vergniol, Julien, Ramee, Jean-François, Bronowicki, Jean-Pierre, Seitz, Jean-François, Legoux, Jean-Louis, Denis, Jacques, Manfredi, Sylvain, Phelip, Jean-Marc

“…[Display omitted] •Phase III, multicenter study, comparing sorafenib + pravastin to sorafenib alone in Child-Pugh A patients with HCC.•The…”
Get full text